ArticleFrontiers in immunology2026
Intermittent parathyroid hormone (1-34) ameliorates periodontitis via Treg-dependent immunomodulation of the Treg/Th17 axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The intermittent administration of parathyroid hormone 1-34 (iPTH) is a bone anabolic therapy with potential for periodontitis treatment, but its immunomodulatory mechanisms remain unclear. This study investigated whether iPTH ameliorates periodontitis by modulating the regulatory T cell (Treg)/T helper cell (Th17) balance. Methods: Experimental periodontitis was induced in mice by ligature. Mice were assigned to control, periodontitis, or iPTH-treated periodontitis groups. Alveolar bone loss was analyzed by micro computed tomography. Bone turnover, cytokines and immune cells were assessed by histology, immunohistochemistry, immunofluorescence, quantitative polymerase chain reaction, and flow cytometry. The role of Tregs was verified via anti-CD25 antibody-mediated depletion. Results: iPTH treatment significantly attenuated alveolar bone loss, improved trabecular microarchitecture, enhanced osteoblast activity, and suppressed osteoclastogenesis. Besides, iPTH suppressed the inflammatory level, downregulating interleukin (IL)-6, IL-17a, receptor activator of nuclear factor-κB ligand (RANKL), while upregulating IL-10. Crucially, iPTH shifted the Treg/Th17 functional axis toward an anti-inflammatory state, increasing Treg proportions in cervical lymph nodes and forkhead box protein P3 (FOXP3) level while simultaneously suppressing IL-17 in gingiva. Furthermore, iPTH reduced the periodontitis-enhanced spatial proximity between FOXP3 and IL-17. Depletion of Tregs impaired the bone-protective effects of iPTH. Conclusions: iPTH ameliorates periodontitis-induced alveolar bone loss through a Treg-dependent mechanism. This identifies the immunomodulation of the Treg/Th17 axis as a pivotal mechanism underlying iPTH's efficacy, highlighting its potential as a host-modulating therapy for periodontitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.